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Lifeng Wang1†, Haijin Chen1†, Jinlong Yu1* , Xiaohua Lin1, Jia Qi1, Chunhui Cui1, Lang Xie1 and Shuxin Huang2
Abstract
Background: Cell-penetrating peptides (CPPs) are a research hotspot due to their noninvasive delivery ability.
Among the identified CPPs, the TAT and R8 peptides have been preferentially applied to transduction into different
cells. However, this process is nonselective among various cells. Recent research suggested that CPP2 could
selectively penetrate human colorectal cancer (CRC) cells.
Methods: Using in vitro experiments, the mean fluorescence intensity of fluorescein isothiocyanate–labeled CPPs
(CPPs-FITC) incubated with different cell lines was compared to corroborate the colon tumor targeting ability
of CPP2. The targeting ability of CPP2 was determined in the same way in tumor-bearing mice. We synthesized
antitumor peptides by fusing CPP2 to the minimal inhibitory sequence of p16 (p16MIS), which had the ability to
restore the function of lost p16, the expression of which was absent in tumor cell lines of various origins. The
antitumor effect of the combined peptide was tested in both CRC cell lines and tumor-bearing mice.
Results: In each CRC cell line, the mean fluorescence intensity of CPP2-FITC was higher than that of the TAT-FITC
(p < 0.001) and R8-FITC (p < 0.001) groups. CPP2-p16MIS, the targeting carrier, showed a higher antitumor response
in the in vitro cell research. CPP2-p16MIS showed a prolonged mean lifespan of tumor-bearing mice, further
characterizing its role in specific tumor-targeting ability in vivo. Survival analysis showed that the mice treated with
CPP2-p16MIS had significantly longer survival than the mice treated with phosphate-buffered saline (p < 0.05) or
those treated with control peptides, including the CPP2 (p < 0.05) and p16MIS (p < 0.05) groups.
Conclusion: CPP2 could more selectively penetrate CRC cells than TAT or R8 as well as effectively deliver the
p16MIS to the tumor.
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Background
Peptides that consist of several cellular or viral proteins
were recently determined able to readily penetrate
cellular plasma membranes. Because of the specialty of
noninvasive and negligibly cytotoxic transport through
macropinocytosis and/or endocytosis, they were named
cell-penetrating peptides (CPPs) [1, 2]. Accordingly,
CPPs have significant biomedical potential as ideal
molecular delivery agents. To date, CPP sequences have
been used to generate CPP–molecular fusion, leading to
the development of cell-permeable peptides/proteins [3],
nucleic acids [4], small interfering RNAs [5], peptide
nucleic acids [6], small-molecule therapeutics [7], quantum
dots [8], and magnetic resonance imaging contrast agents
[9]. For example, TAT peptide, one of the earliest identified
CPPs, has been heavily utilized for its high solubility and
diverse target range [10, 11]. The R8 peptide could also
non-selectively penetrate all neoplastic and non-neoplastic
cells. For these reasons, here we used TAT and R8 as non-
selectively permeable CPP controls.
Although CPPs have been widely used to enhance the
intracellular delivery of various cargoes and nanoparti-
cles [12–14], the poor selection between neoplastic and
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non-neoplastic cells restricted the in vivo application of
the CPPs identified to date [15]. CPP cell specificity is
especially important for cancer therapy to minimize side
effects on normal cells [16]. Therefore, the development
of non-toxic, cancer-specific CPPs for effective cancer
treatments is greatly needed. Kondo, E et al. [17] recently
identified several tumor lineage–homing CPPs, among
which CPP2 could more easily penetrate LoVo human
colon adenocarcinoma cells than other tumor cell lines.
To gain insight into the targeting ability of CPP2 in CRC,
HCT116, SW480, and HL-7702 cells were used for com-
parison with LoVo cells in the in vitro experiments.
Moreover, to investigate whether the in vitro findings
were consistent with in vivo findings, fluorescein isothio-
cyanate (FITC)-labeled CPP delivery was examined in a
mouse model of xenograft human colon tumor cells. We
found that it was possible for CPP2 to target colon
tumor cells and investigated its potential use in peptide-
based molecule delivery systems. We subsequently
attempted to develop a colon tumor–selective molecular
delivery system by leveraging CPP2. Many studies have
shown that p16 mRNA expression was absent in tumor
cell lines of various origins. Loss of p16INK4a expression
is also verified in many different tumors [18–20]. Based
on these results, we synthetized an antitumor peptide by
fusing CPP2 to the minimal inhibitory sequence of p16
(p16MIS), which had the ability to restore the lost p16
function via the GPG sequence [21–23], and generated a
CPP2-fusion peptide for targeting CRC cells.
Methods
Materials
The peptides used in this study were purchased from
Shanghai GL Biochem Corporation Ltd. (Shanghai, China).
RPMI 1640 medium, trypsin-ethylenediaminetetraacetic
acid, fetal bovine serum (FBS), penicillin, and streptomycin
were purchased from Gibco Life Technologies (Grand
Island, NY, USA), while 4′,6-diamidino-2-phenylindole
(DAPI) was obtained from Roche (Basel, Switzerland). The
experiments were performed in thirty-two 4-week-old
BALB/c-nude mice provided by the Animal Experimental
Center of Southern Medical University. The experimental
animals were selected through ethical approval. The study
protocol was approved by the ethics committee of Zhujiang
hospital of Southern Medical University.
Cell lines
HCT116, SW480, and LoVo cells were obtained from
the American Type Culture Collection, which performed
the cell line authentication using DNA fingerprinting by
short tandem repeat analysis. The HL-7702 normal
human hepatocyte cell line was purchased from cell
bank of the Chinese Academy of Sciences (Shanghai,
China), which performed cell line authentication using
the DNA fingerprinting method by monitoring the
DXS52, Apo-B, MD17S5, and D2S44 primers.
Cell viability
Each CPP’s toxicity in each cell line was determined by
trypan blue dye exclusion. The reduction in viable cell
number was examined at the indicated intervals. Cells
were loaded on an automatic cell counter (IC1000;
Countstar, Shanghai, China), and viable cell number was
assessed according to trypan blue dye exclusion.
Peptide synthesis
The amino acid peptide sequences were as follows: CPP2,
DSLKSYWYLQKFSWR; TAT, GRKKRRQRRRPQ; R8,
RRRRRRRR; P16MIS, GPGFLDTLVVLHRGPRRRR; and
CPP2-p16MIS, DSLKSYWYLQKFSWRGPGFLDTLVVLH
RGPRRRR. Here to increase the solubility of CPP2-
p16MIS, four arginine residues were added to the C-
terminus of each peptide via GP spacers. The chemical
solid phase peptide synthesis method was used to
synthesize the peptides as follows: 1. Dissolve proper rink
amide 4-methylbenzhydrylamine resin with dichlorometh-
ane (DCM) and then wash with dimethylformamide
(DMF). 2. Wipe off Fmoc- using hexahydropyridine.
3. Add the first amino acid (AA) Fmoc-AA(trt)-OH
to O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
tetrafluoroborate and N,N-diisopropylethylamine, check-
ing the resin after 1 h of reaction time. 4. Discard the solu-
tion from Step 3 and wash with DMF. 5. Repeat Steps 2–4
until the last AA is produced and FITC is conjugated with
each peptide in the N terminal. 6. Dry the resin after three
washes with DCM, methyl alcohol, and DMF. 7. Rinse off
the resin and protecting group with lysate solution and
then collect the filter liquor and precipitate it by mixing
with diethyl ether. 8. Purify the target peptide using high
performance liquid chromatography until the purity quo-
tient of each peptide is >95 %.
Cell penetration assay
The specific targeting ability of CPP2 was found in LoVo
cells as previously described [17]. However, it remains
unclear whether CPP2 still has this selective permeability
in other tumor cell lines of the same origin. To further
confirm this point in colon tumor cell lines, several
tumor lines, including SW480 and HCT116 cells, were
analyzed in this experiment. HL-7702 and LoVo cells
were incubated as negative and positive controls,
respectively, while TAT and R8 were used for compari-
son with CPP2.
Each cell line was seeded into six-well plates at
2.0 × 105 per well in triplicate and grown in 2.5 mL of
growth medium (90 % RPMI 1640 medium, 10 % FBS)
before the CPP penetration test. The cells were incubated
at 37 °C for 24 h and the permeation tests were conducted
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at approximately 80 % confluence. The culture medium
was replaced with 2.5 mL of mixed growth medium con-
taining 0.3 μM FITC-labeled peptides as previously de-
scribed. The FITC-labeled peptides were first dissolved in
phosphate-buffered saline (PBS) and then added to the
RPMI 1640 medium with FBS. The cells were incubated
with complexes for 12 h at 37 °C, followed by sufficient
washing with PBS to clean the extracellular FITC-CPPs.
The cell nucleus was dyed with DAPI which was then dis-
carded, and the cells were washed thoroughly with PBS.
Each cell line was examined under an inverted fluores-
cence microscope (IX71; OLYMPUS, Tokyo, Japan). Five
areas were chosen and photographed randomly under the
microscopic vision fields (Fig. 1a). Mean fluorescence
intensity (MFI) and the positive area of each picture was
calculated by using Image J software (National Institutes
of Health, Maryland, USA). “Positive rate” here means
fluorescein isothiocyanate (FITC) area/4′,6-diamidino-2-
phenylindole (DAPI) area in the figure.
In vivo fluorescence detection
The in vivo distribution of three FITC-labeled CPPs was
examined 3 h after intraperitoneal injection into tumor-
bearing mice. The tumor mass growing on the nude
mice was examined using an in vivo imaging system
(Kodak in Vivo Imaging System F; Rochester, New York,
USA) to detect the accumulation of the FITC-labeled
peptides.
Survival analysis
Twenty 5-week-old male mice inoculated with SW480
cells were randomly divided into four groups. Two
weeks after the inoculation, CPP2-p16MIS, CPP2,
p16MIS, and PBS were abdominally administered ac-
cordingly. The peptide treatment process was divided
into three courses with a 3-day interval between each. In
each course, CPP2-p16MIS and its counterparts were
administered intraperitoneally every 8 h into the corre-
sponding mice at a dosage of 100 μg per mouse.
Statistical analysis
The data are shown as x ± s. SPSS 21.0 statistical software
was used to process the data using one-way analysis of
variance, while Tukey’s honest significant differences
method was applied to multiple compare among groups
and Kaplan-Meier analysis was used for the survival
analysis.
Results
In vitro fluorescence peptide penetration assay
The intracellular incorporation efficiency of each CPP
was semi-quantitatively measured by the detection of
mean fluorescence intensity against the background
and positive rate. Comparing the mean fluorescence
intensities and positive rates of three CRC cell lines, we
concluded that CPP2 a higher MFI and positive rate
than both R8 and TAT (p < 0.05). Comparison of the
MFI in HL-7702 revealed that neither CPP2 vs R8 nor
CPP2 vs TAT showed any statistically significant differ-
ence (Fig. 1c). Figures 1b even showed the positive rate
of CPP2 in HL-7702 is not higher than R8 (p > 0.05)
and lower than TAT (p < 0.05). The experimental find-
ings indicated that CPP2 was preferentially internalized
by colon adenocarcinoma cells, while R8 and TAT perme-
ated tumor cells relatively poorly by comparison and were
preferentially taken in by HL-7702 (Fig. 1a–c).
In vitro antitumor function test
Antitumor peptides (CPP2-p16MIS) were designed by
fusing CPP2, a cell-penetrating domain, to the p16MIS
to restore the lost p16 function via the GPG sequence.
We explored the anti-tumor function of the synthetic
peptides in CRC cells by comparison with p16MIS and
CPP2. In three repeat experiments, CPP2-p16MIS had
higher cytocidal effects than both CPP2 (p < 0.05) and
p16MIS (p < 0.05). CRC cells treated with CPP2-p16MIS
showed maximal cytocidal effects (approximately 45 %
of the cells were dead 24 h after transduction with the
10 μM peptide). However, the efficiency of p16MIS is
greatly reduced since its lacks the CPP2 portion. As a
transduction domain, CPP2 itself did not demonstrate
cellular toxicity at the same dose. As for the non-
neoplastic HL-7702 cells, none of the three peptides
significantly affected their viability at tumor cell suppres-
sion doses. This might be correlated with the fact that
the p16 protein could be endogenously expressed by
HL-7702. Following a single treatment, approximately
63 % of the cells treated by 10 μM CPP2-p16MIS died at
48 h post-introduction, so we speculated the peptide’s
effect might maintain for at least a few days (Fig. 2a). In
a nutshell, the results showed that the CPP2-p16MIS
peptide, which combined the merits of CPP2 and
p16MIS, could successfully permeate CRC cells and
induce CRC cell apoptosis. Moreover, these data also
suggest that CPP2 would elevate the antitumor efficiency
of p16MIS in particular tumor lineages.
In vivo potential peptide complex application research
To further explore the potential in vivo application of
these peptides, we primarily compared the targeting
ability of the peptides in orthotopically transplanted
models using athymic nude mice. In the first phase,
twelve 4-week-old male mice were randomly divided
into three groups by inoculated cell type. Next, each
nude mouse was subcutaneously inoculated with 5 × 106
CRC cells. Fourteen days post-transplant, the in vivo dis-
tribution of three FITC-labeled CPPs was examined 3 h
after injection. The tumor mass growing on each nude









Fig. 1 (See legend on next page.)
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mouse was detected under the in vivo imaging system
because of the accumulation of the FITC peptides. In
the model mice injected with FITC-CPPs, the fluores-
cent signal from neoplasms derived from FITC-labeled
CPP2 was more intense than that from TAT or R8.
Transection of the cancer mass showed that CPP2
tended to selectively penetrate the tumor. We examined
the in vivo distribution of the fluorescent CPP2 and
compared the fluorescence intensity of the different re-
gions with that of the tumor focus in CRC cell–im-
planted mice. The uptake of intraperitoneally injected
CPP2 in the different body regions was relatively lower
than that of the tumor lesions. Mice injected with TAT
and R8 mainly had hotspots around their lungs (Fig. 3a).
The preferential uptake of CPP2 by the target tumors
was further confirmed with fluorescence images of the
tumor mass and various normal organs, including the
heart, lungs, liver, spleen, intestine, and kidneys (Fig. 3b).
In the mouse model, tumor size did not differ signifi-
cantly among groups 14 days post-transplantation. At
day 24 after inoculation, mice injected with CPP2 and
TAT had larger tumors compared to CPP2-p16MIS and
p16MIS. Tumor growth curves showed that tumors
grew faster in the CPP2 and TAT group. At 29 days
after inoculation, mice injected with CPP2-p16MIS had
smaller tumors and tumors in this group grew slowly
(Fig. 4a). As previously described, the CPP2-p16MIS
peptide could successfully permeate CRC cells and
induce CRC cell apoptosis. Based on these results, we
tested the potential therapeutic utility of CPP2 in vivo.
By day 34 after the abdominal administration of CPP2-
p16MIS, CPP2, p16MIS, and PBS, most of the mice in the
control group (CPP2 or PBS only) had died of aggressive
tumors, while the mice treated with CPP2-p16MIS showed
no significant cachexia at this time point. Survival analysis
(Fig. 4b) showed that the mice treated with CPP2-p16MIS
had a significantly longer survival (mean survival [ms],
42.8 days) than PBS-treated mice (ms, 34.2 days) (p < 0.005)
or mice treated with control peptides, including both CPP2
(ms, 32.6 days) and p16MIS (ms, 37.6 days) (p < 0.005).
Discussion and conclusion
Here we described a kind of CRC-targeting peptide.
CPP2 has the potential to preferentially penetrate CRC
cells. The permeable process shows no significant cyto-
toxicity, which means that CPP2 has the capacity to be
used as an in vivo molecular vehicle. In vivo research,
CPP2 did have the ability to preferentially accumulate in
colonic tumor lesions in sharp contrast to the normal
organs. A well studied protein p16, which had an antitu-
mor potential, here were used to create an antitumor
peptides with CPP2. Compared with CPP2 and p16MIS,
CPP2-p16MIS has the advantages of non-cytotoxic
delivery as well as antitumor properties in targeted CRC
therapy which was confirmed in cell experiments. CPPs
as an emerging biomedical delivery system have been
a b
Fig. 2 In vitro anti-tumor activity test of cell-penetrating peptide 2 (CPP2)-fusion peptide. a The percentage of dead cells in each cell line was
calculated after treatment with four different agents 24 h after administration. aSignificantly different from CPP2 (p≤ 0.05); bsignificantly different from
R8 (p≤ 0.05); and csignificantly different from p16MIS (p≤ 0.05). b The percentage of dead cells in each cell line was calculated after treatment with
four different agents 48 h after administration. aSignificantly different from CPP2 (p≤ 0.05); bsignificantly different from R8 (p≤ 0.05); and csignificantly
different from p16MIS (p≤ 0.05)
(See figure on previous page.)
Fig. 1 a Fluorescence images of three representative cell-penetrating peptides (CPPs) in the different cell lines. Scale bar, 10 μm (amplification
factor, ×200). b Comparisons of the positive rates of the cell lines showed that CPP2, a colon cancer line–homing peptide, had a higher mean
positive rate than that of R8 or TAT (p < 0.05). aSignificantly different from CPP2 (p ≤ 0.05); bsignificantly different from R8 (p ≤ 0.05). c Statistical
analysis showed that CPP2 had higher mean fluorescence intensity than both R8 (p < 0.05) and TAT (p < 0.05) in LoVo, SW480, and HCT116 cells.
Comparisons of CPP2 vs R8 and CPP2 vs TAT showed no statistical significance in HL-7702 cells (p > 0.05). aSignificantly different from CPP2
(p ≤ 0.05); bsignificantly different from R8 (p ≤ 0.05)
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bFig. 3 a In vivo fluorescence imaging of three representative cell-penetrating peptides (CPPs) and phosphate-buffered saline are displayed by
tumor cell line 3 h after the injection of 300 μg of CPPs into nude mice. The tumor mass (red arrow) demonstrated that CPP2 had high selectivity
for colorectal cancer cells. R8 and TAT were employed here as representative non-selectively permeable CPP. Green on black and rainbow were
the two different capture modes. In the rainbow mode, signal intensity here also meant fluorescence intensity, which was reflected by diverse
colors: red > orange > yellow > green > blue (pictured at right). b The tumor mass and organs were excised 3 h after the intraperitoneal injection
of the CPPs. The heart, liver, and spleen are arranged in the first row, the lungs, kidneys, and tumor mass are shown in the second row, and a part
of the small intestine is shown in the last row. Fluorescence imaging of a variety of organs further verified the in vivo imaging results
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highly anticipated since they can translocate across bio-
logical membranes and are capable of transporting their
cargo inside live cells with minimal invasiveness [24].
HIV-1 transcriptional activator TAT protein [10], the
Antennapedia homeodomain of Drosophila [25], and
poly-arginine (n = 4–16) [22, 26] have been the most
widely studied CPPs with respect to enhancing the intra-
cellular delivery of CPP-conjugated molecules. Non-
selective internalization of CPPs into various cells is the
limiting factor for cell-type or tissue-specific targeting
applications such as cancer treatments [11]. Therefore,
the development of a target-specific drug delivery system
is a primary concern for improving the therapeutic effi-
cacy of drugs while reducing their effective doses and
side effects [27]. Van Duijnhoven et al. [28] found that
radiolabeled activatable CPPs can detect matrix metallo-
proteinase activity within tumors. Some studies also
found a few other carriers for drug delivery [27, 29].
Accordingly, many more experiments are needed to cor-
roborate some special CPPs’ ultimate targeting ability.
Here we described the CPP2 structure and demonstrated
its unique function of targeting CRC cells, but its mech-
anism remains unknown. In vivo experiments showed
mice injected with TAT-FITC and R8-FITC mainly had
hotspots around their lungs. This phenomenon might be
correlated with the physical structure of the lungs.
Abundant CPPs absorbed into the blood gathered in the
lung area because of the capillary network that caused
the blood to flow relatively slowly. In addition, we also
observed a lot of CPP uptake in the liver in HCT116
inoculated mice. Whether different CPPs had different
metabolic time in liver still needs more study. The spe-
cial ability of CPP2 might offer a new thought to CRC
diagnosis and treatment. It may also lead to targeted
anticancer therapy in the near future, but the only way
we will realize this beautiful dream is for everyone to
put their shoulders to the wheel.
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Fig. 4 a Tumor growth curve in each group. Tumor volumes were
calculated using the equation V (mm3) = A × B2/2, where A is the
largest diameter, and B is the shortest axis. b Survival analysis results.
CPP2-p16MIS had a significantly longer survival time than PBS-treated
mice or those treated with control peptides (both CPP2 and p16MIS)
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